Cart
sales@molnova.com
Edecesertib
CAS No. 2408839-73-4
Edecesertib( —— )
Catalog No. M35644 CAS No. 2408839-73-4
Edecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameEdecesertib
-
NoteResearch use only, not for human use.
-
Brief DescriptionEdecesertib (GS-5718) is a selective, orally active IRAK-4 inhibitor with anti-inflammatory properties, applicable for the study of rheumatoid arthritis (RA) and lupus erythematosus (LE).
-
DescriptionEdecesertib (GS-5718) is a selective, potent, orally active IRAK-4 inhibitor. Edecesertib has anti-inflammatory activity. Edecesertib can be used for rheumatoid arthritis (RA) and lupus erythematosus (LE) research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetIRAK
-
RecptorIRAK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2408839-73-4
-
Formula Weight435.45
-
Molecular FormulaC22H22FN7O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (229.65 mM; Ultrasonic )
-
SMILESN([C@@H](C#N)C)C=1C=C(C=2N3C(=CC2)C=C(C#N)C=N3)N=CC1C(NC[C@H](C(C)(C)O)F)=O
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Roedder S, et, al. Phase 1 Study Results of GS-5718, an Oral IRAK4-Inhibitor: Pharmacodynamics of Single and Multiple Doses of GS-5718 in Healthy Subjects. 2021 Nov 6.
molnova catalog
related products
-
JH-X-119-01
JH-X-119-01 is a highly potent and selective covalent inhibitor of IRAK-1.
-
IRAK inhibitor 1
IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC50 of 216 nM.
-
Zabedosertib
Zabedosertib (BAY 1834845) is an inhibitor of IRAK4 with immunomodulatory potential. Zabedosertib protects against acute respiratory distress syndrome, a new study suggests.
